This trial is testing if cirmtuzumab, a drug that targets a protein involved in cancer growth, can help treat men with metastatic prostate cancer that has resisted other treatments.
1 Primary · 10 Secondary · Reporting Duration: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months
32 Total Participants · 1 Treatment Group
Primary Treatment: Cirmtuzumab · No Placebo Group · Phase 1
Age 18+ · Male Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: